Medicago begins human testing of flu vaccine

Medicago begins human testing of flu vaccine

Medicago Inc. (TSX-V: MDG) announced a Phase I trial for its H5N1 Avian Influenza vaccine. The Phase I study will evaluate safety, tolerability and the immune response of the Company’s H5N1 vaccine candidate in 48 healthy volunteers between the ages 18 to 60. Results of the study are expected during the fourth quarter of 2009.

Read the release.